康惠制药(603139) - 2024 Q2 - 季度业绩预告

Financial Performance Expectations - The company expects a net profit attributable to shareholders of the parent company for the first half of 2024 to be between -10 million and -7 million RMB, indicating a loss[2]. - Non-recurring gains and losses are estimated to impact the net profit by approximately 7.5 million RMB, leading to a net profit excluding non-recurring items of -17.5 million to -14.5 million RMB[2][18]. - The company reported a net profit attributable to shareholders of the parent company of 12.6 million RMB for the first half of 2023, with a profit total of 11.63 million RMB[16]. Factors Affecting Performance - The delay in production line launch due to uncertainties and significant changes in market demand negatively affected product sales, contributing to the expected losses[6]. - Increased fixed asset depreciation and bank loan interest expenses are anticipated to further impact the company's performance in the first half of 2024[10]. Corporate Actions - The company completed the industrial registration of the buyback of 42.8725% equity held in Kelaivi on June 7, 2024, which may affect future investment income recognition[10]. Financial Reporting Caution - The financial data provided is preliminary and has not been audited by a registered accountant, emphasizing the need for caution among investors[19].